Evidence map›Paper›PMID 35457241›Full record

ArticleInternational journal of molecular sciences2022

A Novel

Lúcia Fadiga, Mariana Lavrador, Nuno Vicente, Luísa Barros, Catarina I Gonçalves, Asma Al-Naama, Luis R Saraiva, Manuel C Lemos

Open access · goldAbstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lúcia FadigaServiço de Endocrinologia, Diabetes e Metabolismo, Centro Hospitalar Universitário de Coimbra, 3000-075 Coimbra, Portugal.ORCID 0000-0002-1513-2722
Mariana LavradorServiço de Endocrinologia, Diabetes e Metabolismo, Centro Hospitalar Universitário de Coimbra, 3000-075 Coimbra, Portugal.
Nuno VicenteServiço de Endocrinologia, Diabetes e Metabolismo, Centro Hospitalar Universitário de Coimbra, 3000-075 Coimbra, Portugal.
Luísa BarrosServiço de Endocrinologia, Diabetes e Metabolismo, Centro Hospitalar Universitário de Coimbra, 3000-075 Coimbra, Portugal.
Catarina I GonçalvesCICS-UBI, Health Sciences Research Centre, University of Beira Interior, 6200-506 Covilhã, Portugal.ORCID 0000-0001-6659-1200
Asma Al-NaamaSidra Medicine, Doha P.O. Box 26999, Qatar.
Luis R SaraivaSidra Medicine, Doha P.O. Box 26999, Qatar.ORCID 0000-0003-4079-0396
Manuel C LemosCICS-UBI, Health Sciences Research Centre, University of Beira Interior, 6200-506 Covilhã, Portugal.ORCID 0000-0001-9326-8900
Hospitais da Universidade de Coimbra · PTUniversity of Beira Interior · PT

Funding

Portuguese Foundation for Science and Technology PTDC/SAU-GMG/098419/2008 and UIDB/00709/2020Sidra Medicine SDR400038
6 · The paper itself

Abstract

Congenital hypogonadotropic hypogonadism (CHH) is a rare reproductive endocrine disorder characterized by complete or partial failure of pubertal development and infertility due to deficiency of the gonadotropin-releasing hormone (GnRH). CHH has a significant clinical heterogeneity and can be caused by mutations in over 30 genes. The aim of this study was to investigate the genetic defect in two siblings with CHH. A woman with CHH associated with anosmia and her brother with normosmic CHH were investigated by whole exome sequencing. The genetic studies revealed a novel heterozygous missense mutation in the Fibroblast Growth Factor Receptor 1 (FGFR1) gene (NM_023110.3: c.242T>C, p.Ile81Thr) in the affected siblings and in their unaffected father. The mutation affected a conserved amino acid within the first Ig-like domain (D1) of the protein, was predicted to be pathogenic by structure and sequence-based prediction methods, and was absent in ethnically matched controls. These were consistent with a critical role for the identified missense mutation in the activity of the FGFR1 protein. In conclusion, our identification of a novel missense mutation of the FGFR1 gene associated with a variable expression and incomplete penetrance of CHH extends the known mutational spectrum of this gene and may contribute to the understanding of the pathogenesis of CHH.

Indexed as

HypogonadismKallmann SyndromeFemaleHumansMaleMutationMutation, MissensePortugalReceptor, Fibroblast Growth Factor, Type 1FGFR1 protein, humanReceptor, Fibroblast Growth Factor, Type 1FGFR1fibroblast growth factor receptor 1geneticshypogonadotropic hypogonadismKallmann syndromemutation

Identifiers

PMID35457241
PMCPMC9026826
OpenAlexW4224001511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.